D. Isenberg, R. Furie, N. S. Jones
May 27, 2021
Citations
0
Influential Citations
41
Citations
Quality indicators
Journal
Arthritis & Rheumatology
Abstract
Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib in systemic lupus erythematosus (SLE) were assessed in this phase II, multicenter, randomized, placebo‐controlled study.